<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR12">
 <label>12.</label>
 <mixed-citation publication-type="other">Molina J-M, Ward D, Brar I, Mills A, Stellbrink H-J, López-Cortés L, et al. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet HIV [Internet]. 2018 Jul [cited 2019 Mar 8];5(7):e357–65. Available from: 
  <ext-link ext-link-type="uri" xlink:href="https://linkinghub.elsevier.com/retrieve/pii/S2352301818300924" xmlns:xlink="http://www.w3.org/1999/xlink">https://linkinghub.elsevier.com/retrieve/pii/S2352301818300924</ext-link>.
 </mixed-citation>
</ref>
